Bristol-Myers Squibb (BMY) wins FDA nod to expand the U.S. label for its blockbuster immunotherapy Opdivo in lung cancer.

Bristol-Myers Squibb Company ( NYSE:BMY ) stock is about to trade ex-dividend in two days. The ex-dividend date is ...

This is a big approval for the company, given that Cobenfy doesn’t have the classic side effects seen in other antipsychotic ...

Bristol-Myers Squibb's acquisition of Karuna and FDA approval of Cobenfy signal growth potential, with focus on driving ...

Bristol Myers Squibb shares rose Friday, a day after its schizophrenia drug was approved for use by the Food and Drug ...

The U.S. Food and Drug Administration (FDA) on Thursday approved Bristol Myers Squibb’s (BMY) highly anticipated ...

(Reuters) - Bristol Myers Squibb won the dismissal on Monday of a $6.4 billion lawsuit claiming it cheated former Celgene ...

Shares in Bristol-Myers Squibb (BMY) surged Friday, after the Food and Drug Administration approved the drugmaker's novel ...

Bristol-Myers Squibb shares rose in premarket trade on Friday after the Food and Drug Administration approved a schizophrenia ...

A federal court in New York has reportedly dismissed a $6.4B suit against Bristol Myers Squibb (NYSE:BMY) that alleged the ...

WARN notices filed with the state show more job cuts due in the health sector as companies look to cut costs and streamline ...

After decades of stagnation in the schizophrenia field, Bristol Myers Squibb’s $14 billion deal for Karuna Therapeutics has ...